Stocks
Single names, sectors, valuations and the trades behind the tape, explained in plain language.
Qantas exits Jetstar Japan in ¥8.2 billion buyback deal
Qantas is exiting Jetstar Japan, selling its 33.32% stake through an 8.2 billion yen share buyback with Japan Airlines. The deal, pending re
Grab lifts 2026 revenue outlook, unveils $750M buyback
Grab raised its 2026 revenue forecast to $4.10-4.15 billion and announced a $750 million share buyback. The ride-hailing and delivery firm's
Danaher names Julie Sawyer Montgomery CEO as Rainer Blair retires
Danaher has chosen Julie Sawyer Montgomery, a longtime executive, to become its next CEO on October 1, succeeding Rainer Blair, who is retir
Cygnus clears takeover hurdle as Australian panel declines challenge
Cygnus Metals says a key obstacle to its takeover of Central Asia Metals has eased after Australia's Takeovers Panel declined to hear a chal
Mexico's SuKarne owner weighs sale valuing meat giant above $2B
The majority owner of SuKarne, one of Mexico's largest meat exporters, is reportedly weighing a sale that could value the company at more th
Sportradar, GameStop, Marriott slide on heavy volume after updates
Sportradar, GameStop, and Marriott all fell sharply on heavy trading after each company delivered news that unsettled investors. Here's what
Visa to Buy Fraud Firm BioCatch for $2.4 Billion as Yields Ease
Visa is paying $2.4 billion in cash for BioCatch, a fraud intelligence firm. The deal comes as 10-year Treasury yields slipped to 4.69%, hel
Atkore jumps on $3.8B Prysmian buyout; Lindblad, Marcus also gain
Atkore jumped after agreeing to a $3.8 billion all-cash takeover by Prysmian. Lindblad Expeditions raised its 2026 revenue outlook, and Marc
Movie stocks shine as Marriott drags on mixed consumer day
Movie theater stocks popped on record box office results, while Marriott slid after a soft quarter. The split shows why 'the consumer' isn't
AstraZeneca and Bristol Myers Squibb in talks for record pharma merger
AstraZeneca and Bristol Myers Squibb are reportedly in talks for a mega-merger that could be the largest in pharma history. Combined, they'd
AbbVie's Next Catalyst: Pipeline Data as Skyrizi Faces Pricing Pressure
RBC Capital Markets says AbbVie's blockbuster drugs Skyrizi and Rinvoq are holding up well, but pricing pressure will persist. The next big
CRH's US infrastructure and data center focus drives Q2 beat, RBC says
CRH's second-quarter results beat expectations, driven by its US infrastructure footprint and data center construction, which offset sluggis